Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OABI
OABI logo

OABI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.340
1 Day change
15.27%
52 Week Range
2.790
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

OmniAb Inc (OABI) is not a strong buy for a long-term beginner investor at this moment. The stock lacks significant positive catalysts, has neutral technical indicators, and no recent trading signals from Intellectia Proprietary Trading Signals. Additionally, there is no substantial financial or news data to support a strong buy recommendation. Given the investor's impatience and preference for long-term investments, holding off on this stock is advisable.

Technical Analysis

The MACD histogram is negative (-0.0713) and contracting, indicating weak momentum. RSI is neutral at 55.753, and moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 2.308, R1: 2.56, S1: 2.056, R2: 2.716, S2: 1.9. The stock's price is near the pivot point, suggesting indecision in the market.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
10

Positive Catalysts

  • No recent news or significant positive catalysts identified. The stock has a 10.51% chance of increasing in the next month based on similar candlestick patterns.

Neutral/Negative Catalysts

  • Post-market price dropped by -3.21%. The stock has a -3.25% chance of declining in the next week based on similar candlestick patterns. No significant hedge fund or insider trading activity. No recent congress trading data.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess the company's growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available, leaving no insight into Wall Street sentiment.

Wall Street analysts forecast OABI stock price to rise
6 Analyst Rating
Wall Street analysts forecast OABI stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.030
sliders
Low
3
Averages
6.8
High
11
Current: 2.030
sliders
Low
3
Averages
6.8
High
11
Craig-Hallum
Buy
downgrade
$10 -> $7
AI Analysis
2025-11-05
Reason
Craig-Hallum
Price Target
$10 -> $7
AI Analysis
2025-11-05
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.

People Also Watch